How do I diagnose late‑onset type 1 diabetes in an adult presenting with unexplained hyperglycemia?

Diagnosing Late-Onset Type 1 Diabetes in Adults

Test islet autoantibodies (GAD, IA-2, ZnT8) as the primary diagnostic step in any adult with unexplained hyperglycemia who has clinical features suggesting type 1 diabetes, and measure C-peptide if the patient is already on insulin to confirm insulin deficiency. 1

Clinical Features That Should Trigger Testing

Look for these specific red flags that distinguish late-onset type 1 diabetes from type 2 diabetes:

• Younger age at diagnosis (<35 years, though can occur at any age)
• Unintentional weight loss or lean body habitus (though obesity does NOT exclude type 1 diabetes) 1, 2
• Diabetic ketoacidosis (DKA) at presentation or early in disease course
• Rapid progression to insulin requirement (within weeks to months)
• Poor response to non-insulin diabetes medications 3
• Personal or family history of autoimmune disorders 3
• Absence of metabolic syndrome features (though these can coexist) 3

Important caveat: Adults with type 1 diabetes present differently than children—only 32.6% of adults present with DKA compared to 56% of children, and adults over 40 years present with DKA only 13% of the time 4. This makes diagnosis more challenging and contributes to the fact that at least one in three adults with type 1 diabetes are initially misdiagnosed as having type 2 diabetes 5.

Diagnostic Algorithm

Step 1: Islet Autoantibody Testing

Order GAD antibodies first as the primary screening test 1:

• If GAD is positive → confirms autoimmune type 1 diabetes
• If GAD is negative → follow with IA-2 and/or ZnT8 antibodies where available
• Insulin autoantibodies can be useful if the patient has not yet been treated with insulin

Critical interpretation point: In adults diagnosed at <35 years with no features of type 2 diabetes or monogenic diabetes, a negative antibody result does NOT exclude type 1 diabetes, since 5-10% of people with type 1 diabetes are antibody-negative 1. Adults more often present with zero or one autoantibody compared to children (43% vs. 20.2%) 4.

Step 2: C-Peptide Testing (If Patient Is on Insulin)

Measure C-peptide only if the patient is already receiving insulin treatment 1:

• Random C-peptide (with concurrent glucose) within 5 hours of eating can replace formal stimulation testing
• Interpretation:
  • <200 pmol/L (<0.6 ng/mL) → confirms type 1 diabetes with severe insulin deficiency
  • 200-600 pmol/L (0.6-1.8 ng/mL) → indeterminate, consider repeat testing
  • >600 pmol/L (>1.8 ng/mL) → suggests type 2 diabetes

Testing caveats:

• Do not test within 2 weeks of hyperglycemic crisis
• If concurrent glucose is <4 mmol/L (<70 mg/dL) or patient may have been fasting, repeat the test
• Very low levels (<80 pmol/L) do not need repeating
• C-peptide must be measured BEFORE discontinuing insulin 1

Step 3: Age-Based Decision Making for Antibody-Negative Cases

If autoantibodies are negative:

• Age <35 years with NO features of type 2 diabetes → Still diagnose as type 1 diabetes (5-10% are antibody-negative) 1
• Age >35 years → Make clinical decision based on:
  • Presence of type 2 diabetes features (obesity, metabolic syndrome, family history of type 2)
  • Consider trial of non-insulin therapy if appropriate 1
  • Consider C-peptide testing after >3 years duration to reassess classification

Common Diagnostic Pitfalls

1. Assuming obesity excludes type 1 diabetes: Obesity is increasingly common in adults with type 1 diabetes and does not rule out the diagnosis 2, 5

2. Relying on single positive antibody in low-risk populations: In adults without clinical features of type 1 diabetes, a single positive antibody likely represents a false positive due to low disease prevalence 6. This is why clinical features matter.

3. Missing the diagnosis because DKA is absent: Adults, especially those >40 years, frequently present without DKA and may have a more gradual onset 4, 7

4. Not testing antibodies at all: Autoantibody testing is underutilized in adults, leading to widespread misclassification 5

5. Testing antibodies in patients with clear type 2 diabetes features: This increases false-positive rates. Only test when clinical features suggest type 1 diabetes 6

Special Considerations for Older Adults

In adults diagnosed after age 30-40 years, the presentation is more heterogeneous 7:

• Progression may be slower than in children
• May retain some β-cell function for months to years
• Higher rates of misclassification due to type 2 diabetes prevalence
• Consider monogenic diabetes if A1C <7.5% at diagnosis, one parent with diabetes, or specific syndromic features 1

Standardized islet autoantibody tests are recommended for classification of diabetes in adults who have phenotypic risk factors that overlap with type 1 diabetes 1. This testing is essential because accurate classification determines appropriate treatment, prognosis, and access to disease-modifying therapies.